Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Record History

1. Minor Oct 5, 2026 Collaborators revised (3)
2. Notable Sep 24, 2026 Sponsor changed: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair to Medicine Invention Design, Inc Primary endpoints: details revised at 2 of 2 entries · Eligibility criteria expanded, about 29 words · Study description expanded, about 8 words · 1 more Show 4 more changesShow less

   • Primary endpoints: details revised at 2 of 2 entries
   • Eligibility criteria expanded, about 29 words
   • Study description expanded, about 8 words
   • Collaborators: 2 to 3
3. Notable Aug 20, 2026 Sponsor changed: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair to Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair Trial arms changed: 2 → 1 · Interventions: Alectinib (Drug) to ALECENSA - alectinib hydrochloride capsule (Drug) · Eligibility criteria shortened, about 10 wordsv25 Show 3 more changesShow less

   • Trial arms changed: 2 → 1
   • Interventions: Alectinib (Drug) to ALECENSA - alectinib hydrochloride capsule (Drug)
   • Eligibility criteria shortened, about 10 words

   See this version in full on ClinicalTrials.gov ↗

4. Notable Aug 18, 2026 Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair to Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair Interventions: Alectinib - Study (Drug), Alectinib - Usual (Drug) to Alectinib (Drug) · Study arms: 2 to 1 · Eligibility criteria shortened, about 4 words · 1 morev24 Show 4 more changesShow less

   • Interventions: Alectinib - Study (Drug), Alectinib - Usual (Drug) to Alectinib (Drug)
   • Study arms: 2 to 1
   • Eligibility criteria shortened, about 4 words
   • Study description shortened, about 4 words

   See this version in full on ClinicalTrials.gov ↗

5. Minor Jun 27, 2026 Re-verified, no change to tracked fieldsv23
6. Minor Jun 12, 2026 Study title shortened, about 1 wordv22 See this version in full on ClinicalTrials.gov ↗
7. Notable May 28, 2026 Primary endpoint(s) modified Eligibility criteria expanded, about 2 words · Study description expanded, about 2 wordsv21 Show 2 more changesShow less

   • Eligibility criteria expanded, about 2 words
   • Study description expanded, about 2 words

   See this version in full on ClinicalTrials.gov ↗

8. Notable May 26, 2026 Primary endpoints: 3 to 2 Eligibility criteria expanded, about 41 wordsv20 Show 1 more changeShow less

   • Eligibility criteria expanded, about 41 words

   See this version in full on ClinicalTrials.gov ↗

9. Notable May 20, 2026 Primary endpoint(s) modified Eligibility criteria expanded, about 9 wordsv19 Show 1 more changeShow less

   • Eligibility criteria expanded, about 9 words

   See this version in full on ClinicalTrials.gov ↗

10. Minor Apr 25, 2026 Collaborators: 1 to 2v18 See this version in full on ClinicalTrials.gov ↗
11. Minor Apr 23, 2026 Study sites: 1 to 2v17
12. Minor Apr 9, 2026 Study title expanded, about 1 wordv16 See this version in full on ClinicalTrials.gov ↗
13. Minor Mar 29, 2026 Study title shortened, about 1 wordv15 See this version in full on ClinicalTrials.gov ↗
14. Notable Mar 21, 2026 Start date changed from estimate of Nov 8, 2025 to Mar 18, 2026 Trial status: Not Yet Recruiting to Active, Not Recruiting · Study site revised · Study title revisedv14 Show 3 more changesShow less

    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study site revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

15. Notable Jun 4, 2025 Primary completion date: Nov 18, 2025 to Nov 18, 2026 Start date: Nov 8, 2024 to Nov 8, 2025 · Completion date: Dec 28, 2025 to Dec 28, 2026v13 Show 2 more changesShow less

    • Start date: Nov 8, 2024 to Nov 8, 2025
    • Completion date: Dec 28, 2025 to Dec 28, 2026
16. Minor Aug 30, 2024 Collaborators expanded, about 1 wordv12 See this version in full on ClinicalTrials.gov ↗
17. Notable Aug 9, 2024 Primary completion date: Nov 18, 2024 to Nov 18, 2025 Start date: Mar 8, 2024 to Nov 8, 2024 · Completion date: Dec 28, 2024 to Dec 28, 2025 · Eligibility criteria shortened, about 10 words · 1 morev11 Show 4 more changesShow less

    • Start date: Mar 8, 2024 to Nov 8, 2024
    • Completion date: Dec 28, 2024 to Dec 28, 2025
    • Eligibility criteria shortened, about 10 words
    • Study description shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

18. Minor Dec 27, 2023 Study description revised Eligibility criteria shortened, about 2 wordsv10 Show 1 more changeShow less

    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

19. Notable Dec 13, 2023 Primary completion date: May 18, 2024 to Nov 18, 2024 Start date: Nov 8, 2023 to Mar 8, 2024 · Completion date: May 28, 2024 to Dec 28, 2024v9 Show 2 more changesShow less

    • Start date: Nov 8, 2023 to Mar 8, 2024
    • Completion date: May 28, 2024 to Dec 28, 2024
20. Minor Oct 20, 2023 Re-verified, no change to tracked fieldsv8
21. Notable Oct 18, 2023 Start date: Sep 8, 2023 to Nov 8, 2023 Trial status: Active, Not Recruiting to Not Yet Recruiting · Study description shortened, about 6 words · Site contact updated · 1 morev7 Show 4 more changesShow less

    • Trial status: Active, Not Recruiting to Not Yet Recruiting
    • Study description shortened, about 6 words
    • Site contact updated
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

22. Minor Oct 4, 2023 Trial status: Not Yet Recruiting to Active, Not Recruiting Site contact updatedv6 Show 1 more changeShow less

    • Site contact updated
23. Minor Sep 5, 2023 Re-verified, no change to tracked fieldsv5
24. Notable Aug 31, 2023 Primary endpoint revised Start date: Sep 28, 2023 to Sep 8, 2023 · Interventions: Crizotinib - Study (Drug), Crizotinib - Usual (Drug) to Alectinib - Study (Drug), Alectinib - Usual (Drug) · Study title revised · 2 morev4 Show 5 more changesShow less

    • Start date: Sep 28, 2023 to Sep 8, 2023
    • Interventions: Crizotinib - Study (Drug), Crizotinib - Usual (Drug) to Alectinib - Study (Drug), Alectinib - Usual (Drug)
    • Study title revised
    • Eligibility criteria expanded, about 2 words
    • Study description expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

25. Minor Aug 15, 2023 Re-verified, no change to tracked fieldsv3
26. Notable Aug 13, 2023 Primary endpoint revised Interventions: Alectinib - Study (Drug), Alectinib - Usual (Drug) to Crizotinib - Study (Drug), Crizotinib - Usual (Drug) · Site contact updated · Study title revised · 2 morev2 Show 5 more changesShow less

    • Interventions: Alectinib - Study (Drug), Alectinib - Usual (Drug) to Crizotinib - Study (Drug), Crizotinib - Usual (Drug)
    • Site contact updated
    • Study title revised
    • Eligibility criteria shortened, about 2 words
    • Study description shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

27. Minor Aug 4, 2023 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.